Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy

Electroporation is a process that causes a transient increase in the permeability of cell membranes. It can be used to increase the intracellular concentration of chemotherapeutic agents in tumor cells (electrochemotherapy; ECT). A clinical study was initiated to determine if this mode of treatment would be effective against certain primary and metastatic cutaneous malignancies. A group of six patients, three with malignant melanoma, two with basal cell carcinoma, and one with metastatic adenocarcinoma, were enrolled in the study. The treatment was administered in a two‐step process.

[1]  J. Weaver,et al.  Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[2]  L. Mir,et al.  Systemic Antitumor Effects of Electrochemotherapy Combined with Histoincompatible Cells Secreting Interleukin‐2 , 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[3]  L. Mir,et al.  Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host's defenses. , 1992, European cytokine network.

[4]  J. Weaver,et al.  Electroporation: A general phenomenon for manipulating cells and tissues , 1993, Journal of cellular biochemistry.

[5]  M. Okino,et al.  Optimal Electric Conditions in Electrical Impulse Chemotherapy , 1992, Japanese journal of cancer research : Gann.

[6]  G. A. Hofmann,et al.  Electrochemotherapy--a novel method of cancer treatment. , 1994, Cancer treatment reviews.

[7]  M. Ogihara,et al.  Potentiation of antitumor effect of bleomycin by local electric pulses in mouse bladder tumor. , 1994, The Tohoku journal of experimental medicine.

[8]  A Brun,et al.  A new brain tumour therapy combining bleomycin with in vivo electropermeabilization. , 1993, Biochemical and biophysical research communications.

[9]  M. Jaroszeski,et al.  Treatment of B16 mouse melanoma with the combination of electropermeabilization and chemotherapy. Bioelectrochem , 1995 .

[10]  H. Potter,et al.  Electroporation in biology: methods, applications, and instrumentation. , 1988, Analytical biochemistry.

[11]  L. Mir,et al.  Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: direct access to the cytosol. , 1988, Experimental cell research.

[12]  L. Mir,et al.  Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. , 1991, European journal of cancer.

[13]  L. Mir,et al.  Electrochemotherapy of spontaneous mammary tumours in mice. , 1991, European journal of cancer.

[14]  L. Hafström,et al.  Regional chemotherapy for malignant melanoma. , 1993, Cancer treatment reviews.

[15]  L. Mir,et al.  Electrochemotherapy: variable anti-tumor effect on different tumor models , 1994 .

[16]  R. Yeung.  Management of recurrent cutaneous melanoma. , 1994, Current problems in cancer.

[17]  L. Mir,et al.  Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. , 1988, Biochemical pharmacology.

[18]  J. Weaver,et al.  Tissue electroporation. Observation of reversible electrical breakdown in viable frog skin. , 1989, Biophysical journal.

[19]  R. Auerbach,et al.  Regional differences in the incidence and growth of mouse tumors following intradermal or subcutaneous inoculation. , 1978, Cancer research.

[20]  R. Heller,et al.  Transfer of human membrane surface components by incorporating human cells into intact animal tissue by cell-tissue electrofusion in vivo. , 1990, Biochimica et biophysica acta.

[21]  E. Haller,et al.  Electrofusion of individual animal cells directly to intact corneal epithelial tissue. , 1989, Biochimica et biophysica acta.

[22]  A. Buzaid,et al.  Chemotherapy for advanced malignant melanoma , 1992, International journal of clinical & laboratory research.

[23]  L. Mir,et al.  Electrochemotherapy, a new antitumor treatment. First clinical phase I‐II trial , 1993, Cancer.